Should I buy or sell Vera Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VERA shares. View VERA analyst ratings or view top-rated stocks .

What is Vera Therapeutics' stock price target for 2024?

8 analysts have issued twelve-month price objectives for Vera Therapeutics' stock. Their VERA share price targets range from $22.00 to $56.00. On average, they expect the company's stock price to reach $32.29 in the next year. This suggests that the stock has a possible downside of 18.2%. View analysts price targets for VERA or view top-rated stocks among Wall Street analysts .

How have VERA shares performed in 2024?

Vera Therapeutics' stock was trading at $15.38 at the beginning of 2024. Since then, VERA shares have increased by 156.7% and is now trading at $39.48. View the best growth stocks for 2024 here .

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VERA earnings forecast .

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) posted its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.05.

What ETFs hold Vera Therapeutics' stock?

ETFs with the largest weight of Vera Therapeutics (NASDAQ:VERA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , ALPS Medical Breakthroughs ETF (SBIO) , SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) . iShares Micro-Cap ETF (IWC) .

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VERA

Vera Therapeutics (VERA) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free VERA Stock Alerts

$39.48

-0.53 (-1.32%)

(As of 04/18/2024 ET)

Compare

Today's Range: $38.83
▼
$40.71
50-Day Range: $37.41
▼
$49.14
52-Week Range: $6.07
▼
$50.78

Volume: 856,999 shs
Average Volume: 1.31 million shs
Market Capitalization: $2.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.29

Get Vera Therapeutics alerts:

Vera Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 18.2% Downside
$32.29 Price Target
Short Interest: Bearish
16.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 11 Articles This Week
Insider Trading: Selling Shares
$21.53 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.26) to ($2.45) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.61 out of 5 stars

Medical Sector

861st out of 918 stocks

Pharmaceutical Preparations Industry

378th out of 402 stocks

1.5

Analyst's Opinion

Consensus Rating
Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Vera Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.12% of the float of Vera Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Vera Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Vera Therapeutics has recently increased by 1.44%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Vera Therapeutics does not currently pay a dividend.
Dividend Growth
Vera Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERA.

2.5

News and Social Media Coverage

News Sentiment
Vera Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Vera Therapeutics this week, compared to 3 articles on an average week.
Search Interest
11 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vera Therapeutics insiders have sold 330.67% more of their company's stock than they have bought. Specifically, they have bought $4,999,990.00 in company stock and sold $21,533,345.00 in company stock.
Percentage Held by Insiders
21.70% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.26) to ($2.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vera Therapeutics is -17.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vera Therapeutics is -17.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vera Therapeutics has a P/B Ratio of 20.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Vera Therapeutics Stock (NASDAQ:VERA)

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

VERA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VERA Stock News Headlines

April 13, 2024 | insidertrades.com

Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of Stock

April 8, 2024 | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in Stock

April 18, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

March 26, 2024 | insidertrades.com

Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells 340,000 Shares of Stock

March 26, 2024 | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi Sells 81,009 Shares

April 16, 2024 | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider Selling

April 14, 2024 | investing.com

Vera Therapeutics executive sells over $228k in company stock

April 14, 2024 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells $228,560.00 in Stock

April 18, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

April 13, 2024 | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase

April 13, 2024 | fool.com

Could This Stock Be the Next Biotech Buyout?

April 12, 2024 | finance.yahoo.com

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

April 11, 2024 | msn.com

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 10, 2024 | msn.com

Alpine Immune jumps on report of takeover interest

April 9, 2024 | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider Selling

April 7, 2024 | nasdaq.com

Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options

April 3, 2024 | seekingalpha.com

Vera Therapeutics: Waiting For A Pullback

March 26, 2024 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Vera Therapeutics Ahead of Key Atacicept Clinical Milestones

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vera Therapeutics with Promising Trials and Strong Financial Runway

March 20, 2024 | benzinga.com

Vera Therapeutics: Q4 Earnings Insights

March 20, 2024 | msn.com

Vera Therapeutics GAAP EPS of -$2.25 misses by $0.07

March 20, 2024 | investorplace.com

VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023

March 20, 2024 | globenewswire.com

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 17, 2024 | bbc.co.uk

Weekend Woman’s Hour: Irish folk singer Cara Dillon, The Hampstead Paedophile Hoax, Maximalism

March 16, 2024 | finance.yahoo.com

VERA Mar 2024 17.500 call

March 16, 2024 | ca.finance.yahoo.com

VERA Apr 2024 40.000 call

See More Headlines

Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VERA
CUSIP: N/A
CIK: 1831828
Web: veratx.com
Phone: 650-770-0077
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.29
High Stock Price Target: $56.00
Low Stock Price Target: $22.00
Potential Upside/Downside: -18.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,990,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.33%
Return on Assets: -50.79%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 7.71
Quick Ratio: 7.71

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.94 per share
Price / Book: 20.35

Miscellaneous

Outstanding Shares: 54,450,000
Free Float: 42,636,000
Market Cap: $2.15 billion
Optionable: Optionable
Beta: 1.05

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Sean P. Grant M.B.A. (Age 39)
Chief Financial Officer
Comp: $585.5k
Mr. Joseph R. Young M.B.A. (Age 51)
Senior VP of Finance & Chief Accounting Officer
Mr. Julien E. Capers J.D.
VP & Head of Legal
Ms. Kelly Rauber
VP & Head of Human Resources
Mr. Tom Doan (Age 52)
Senior Vice President of Development Operations
Ms. Lauren Frenz (Age 39)
Chief Business Officer
Dr. Neeraj Pakala M.B.A.
Ph.D., Senior VP and Head of Product Development & Manufacturing
Dr. Kerry Cooper M.D.
Senior Vice President of Medical Affairs
Dr. Robert M. Brenner M.D. (Age 56)
Chief Medical Officer
Mr. William D. Turner (Age 57)
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VERA shares.
View VERA analyst ratings or view top-rated stocks.
What is Vera Therapeutics' stock price target for 2024?: 8 analysts have issued twelve-month price objectives for Vera Therapeutics' stock. Their VERA share price targets range from $22.00 to $56.00. On average, they expect the company's stock price to reach $32.29 in the next year. This suggests that the stock has a possible downside of 18.2%.
View analysts price targets for VERA or view top-rated stocks among Wall Street analysts.
How have VERA shares performed in 2024?: Vera Therapeutics' stock was trading at $15.38 at the beginning of 2024. Since then, VERA shares have increased by 156.7% and is now trading at $39.48.
View the best growth stocks for 2024 here.
When is Vera Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERA earnings forecast.

How were Vera Therapeutics' earnings last quarter?: Vera Therapeutics, Inc. (NASDAQ:VERA) posted its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.05.
What ETFs hold Vera Therapeutics' stock?: ETFs with the largest weight of Vera Therapeutics (NASDAQ:VERA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC).
When did Vera Therapeutics IPO?: Vera Therapeutics (VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.
How do I buy shares of Vera Therapeutics?: Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial